A clinical study of perfusion weighted magnetic resonance imaging in recombinant human endostatin combined with chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma

Abstract

Objective To assess the antiangiogenic role of recombinant human endostatin combined with chemoradiotherapy and the capacity, and to explore the early tumor response as measured by comparing the change of MRI perfusion parameter. Methods From May 2012 to March 2013, 22 locally advanced nasopharyngeal carcinoma patients who received recombinant human endostatin combined with chemoradiotherapy following induction chemotherapy, were included in the prospective study group. The other 25 patients, who received chemoradiotherapy following induction chemotherapy alone in the same period, were included in the control group. The perfusion parameters including blood volume(BV), blood flux(BF), mean transit time(MTT) were obtained by carrying out MR perfusion scanning at 3 time points: before induction chemotherapy, after induction chemotherapy, the end of concurrent chemoradiotherapy. Results Compared with before induction chemotherapy, the perfusion parameters including BV and BF obviously decreased in the study group(F=3.05, 3.85, P 0.05). In the control group, the change of BV, BF and MTT of nasopharyngeal lesions area during the treatment showed no significant difference(P>0.05). To make comparison between the two groups, at the end of concurrent chemoradiotherapy, BF of nasopharyngeal lesions area in the study group was 0.72±0.56 and 1.92±1.26 in the control group, the former showing significantly declined results(t=-3.056, P=0.012). Conclusions Recombinant human endostatin might be a good indicator of local tumor microvascular changes and the treatment-related toxicity could be tolerated. Magnetic resonance perfusion imaging maybe assessed the capacity of anti-angiogenesis therapy to induce early tumor response. Clinical trial registration Chinese clinical trial registry, ChiCRT-ONRC-12002394. Key words: Recombinant human endostatin; Nasopharyngeal carcinomac; Induction chemotherapy; Concurrent chemoradiotherapy; Magnetic resonance perfusion imaging